Gevo Reports Fourth Quarter 2015 Financial Results
Mar 29, 2016 11:10 am UTC| Business
Gevo Restarts Production of Isobutanol in March 2016 Following Completion of Capital Projects - Gevo to Host Conference Call Today at 5:30 EDT/3:30 MDT -Reports EPS of ($0.44) for the fourth quarterEnded the fourth quarter...
Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
Mar 29, 2016 11:05 am UTC| Business
Study Commences Second Dose-Escalation Cohort 90-Patient Phase II Combination Trial in Cervical and Head and Neck Cancer to Begin Mid-Year PRINCETON, N.J., March 29, 2016 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical...
Mar 29, 2016 11:05 am UTC| Business
SAN RAMON, Calif., March 29, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet...
Mar 29, 2016 11:05 am UTC| Business
SAN CLEMENTE, Calif., March 29, 2016 -- CareTrust REIT, Inc. (Nasdaq:CTRE) announced the closing of its underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $11.35 per share....
Gevo Announces Pricing of $3.5 Million Public Offering of Common Stock and Warrants
Mar 29, 2016 11:01 am UTC| Business
ENGLEWOOD, Colo., March 29, 2016 -- Gevo, Inc. (NASDAQ:GEVO), a leading renewable chemicals and next-generation biofuels company, announced today that it has priced its underwritten public offering of common stock and...
Mar 29, 2016 11:00 am UTC| Business
RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORT™ in Spain, and a right of...
Mar 29, 2016 11:00 am UTC| Business
NEW YORK, March 29, 2016 -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that it has reached an agreement on the...